Italian CDMO Olon is to invest €10 million to create an R&D hub at its headquarters site at Rodano near Milan. This will integrate seven existing R&D centres and will be dedicated entirely to research laboratories to be used to develop APIs and manufacturing processes.
Construction has started and is due to be completed in Q2 2023. This will also lead to about 50 new researchers being hired, bringing the corporate total to around 350.
Hanmi Fine Chemical, an API manufacturing subsidiary of Hanmi Pharmaceutical, has announced plans for a new business offering what it calls ‘high-tech CDMO’ services. It will spend €7.4 million to build facilities for them and expects to form partnerships with more companies in 2H 2022, in addition to the ten it already has.
A little flexibility in approach will improve consistency and enable pharma partners to perform to their optimum level. Ahead of her presentation on ‘How to Build a ‘Framework for Managing Your Outsourcing Partner’ at CPhI North America, we spoke with Stephanie Gaulding, executive director of regulatory compliance at Pharmatech Associates
CDMO EuroAPI has been listed on the Euronext Paris market as of 5 May. CEO Karl Rotthier said that the listing “marks an exciting milestone for the development of our company as it will enable us to consolidate our leadership in the dynamic API market”.
Private equity firm Atorg has agreed to acquire CDMO CordenPharma from International Chemical Investors Group (ICIG), subject to customary regulatory approvals. The founders, Patrick Schnitzer and Dr Achim Riemann, will also reinvest in the firm and CEO Michael Quirmbach remains in place.
CDMO Onyx Scientific has opened a second facility at its headquarters site in Sunderland, UK.This doubles its footprint and allows for expansion of all CMC activities, including additional GMP facilities that increases capacity for GMP and commercial API manufacturing capacity by 50%.
Dow has announced plans to expand its alkoxylation capacity in the US and Europe in 2024 and 2025. The investments are backed by supply agreements with customers and are being made to meet 10-15%/year growth in end markets including home and personal care, industrial and institutional cleaning, pharmaceuticals and crop protection.
